Organization & Leadership
To accomplish its mission, SCB operates in partnership with industry, academia, government agencies, regulatory bodies, and standards development organizations (SDOs) involved in establishing consensus standards for regenerative medicine and other advanced therapy products.
SCB’s leadership guides the organization in its mission to coordinate the accelerated advancement of standards for the regenerative medicine community.
Executive Committee
Richard McFarland
President
Jessica Carmen
Vice President
April Lynch
Secretary
Michael Orrico
Treasurer
Board of Directors
JESSICA CARMEN, Adjuvant Partners
KURT GUNTER, Kuur Therapeutics
NAYNESH KAMANI
MIKE KELLY, Atsena Therapeutics
SVEN KILI, Sven Kili Consulting
MIKE LEHMICKE, Alliance for Regenerative Medicine (ARM)
APRIL LYNCH, CSafe Global
JENNIFER MANTLE, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
RICHARD MCFARLAND, Advanced Regenerative Manufacturing Institute (ARMI)
MICHAEL MENDICINO, Hybrid Concepts International
MICHAEL ORRICO, Shepherd Payne Associates
ERIC ROOS, Aspect Biosystems
KRISHNENDU ROY, Georgia Institute of Technology
MORRIE RUFFIN, Adjuvant Partners
MITCH SIVILOTTI, CCRM
JASON WERTHEIM, University of Arizona College of Medicine - Tucson
ELIZABETH S. WOO, Thermo Fisher Scientific
YUTAKA YANAGITA, Forum for Innovative Regenerative Medicine (FIRM)
JIWEN ZHANG, Renovacor
CLAUDIA ZYLBERBERG, Akron Biotech
SCB LIAISONS
SHENG-LIN GIBSON, National Institute of Standards and Technology (NIST)
ANNE PLANT, National Institute of Standards and Technology